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Background. Neuroendocrine markers, which could indicate for aggressive variants of prostate cancer and Ki67 (a 
well-known marker in oncology for defining tumor proliferation), have already been associated with clinical outcome 
in prostate cancer. The aim of this study was to investigate the prognostic value of those markers in primary prostate 
cancer patients.
Patients and methods. NSE (neuron specific enolase), ChrA (chromogranin A), Syp (Synaptophysin) and Ki67 stain-
ing were performed by immunohistochemistry. Then, the prognostic impact of their expression on overall survival was 
investigated in 166 primary prostate cancer patients by univariate and multivariate analyses.
Results. NSE, ChrA, Syp and Ki67 were positive in 50, 45, 54 and 146 out of 166 patients, respectively. In Kaplan-Meier 
analysis only diffuse NSE staining (negative vs diffuse, p = 0.004) and Ki67 (≤ 10% vs > 10%, p < 0.0001) were significantly 
associated with overall survival. Ki67 expression, but not NSE, resulted as an independent prognostic factor for overall 
survival in multivariate analysis. 
Conclusions. A prognostic model incorporating Ki67 expression with clinical-pathological covariates could provide 
additional prognostic information. Ki67 may thus improve prediction of prostate cancer outcome based on standard 
clinical-pathological parameters improving prognosis and management of prostate cancer patients.
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Introduction
Conventional clinical parameters alone are inad-
equate for differentiating indolent and aggressive 
prostate cancer. Therefore, molecular biomarkers 
are needed to better define prognosis of prostate 
cancer patients.
Neuroendocrine markers could be used to detect 
particularly aggressive variants of prostate cancer. 
Typical markers used to identify neuroendocrine 
differentiation (NED) in tumor tissue are neuron 
specific enolase (NSE), chromogranin A (CgA) and 
synaptophysin (Syp).1-3 Neuroendocrine differen-
tiation, measured by one or more of those mark-
ers, has been associated with disease progression4 
or poor survival in prostate cancer5, but up to now 
its prognostic value has not been clarified because 
of controversial results6;7,8. However, Epstein et al.9 
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have recently suggested using neuroendocrine 
markers to better characterize and classify NED in 
prostate cancer. They also outlined Ki67 ranges in 
those tumors, which usually have a high prolifera-
tive index.4,9-13 Ki67 is a well-known marker in on-
cology for defining tumor proliferation. Expression 
of Ki67 detection by immunohistochemistry14 is 
used as a prognostic marker for cell proliferation 
in many tumors, especially in breast carcinoma15 
and cervical cancer.16 In prostate cancer it has also 
been associated with clinical outcome, irrespective 
of treatment.4,17-27
The aims of this study were to 1) investigate the 
immunohistochemical expression of neuroendo-
crine and Ki67 markers in primary prostate cancer 
patients in order to identify tumors characterized 
by biological aggressiveness and poor prognosis, 
2) evaluate neuroendocrine expression with re-
spect to Ki67 staining.
Patients and methods
Patients
Detailed histopathological and clinical data were 
retrospectively collected for 166 patients, who were 
diagnosed with primary prostate cancer in a single 
institution of the North-eastern Italy from January 
1992 to December 1994, therefore associated to a 
long follow-up period. Inclusion criteria for this 
study were: a) diagnosis of prostate cancer and b) 
availability of formalin-fixed and paraffin-embed-
ded tissues for immunohistochemical staining and 
molecular analyses. Only TURP (N = 122, 73.9%) 
and prostatectomy (N = 43, 26.1%) specimens were 
used (missing information for one patient). Fine 
needle biopsies were excluded because of the low 
amount of tissue. Patients did not receive any treat-
ment before diagnosis. The use of formalin-fixed 
and paraffin-embedded prostate cancer tissues and 
their related clinical information were approved by 
the Ethical Committee of the University of Trieste 
(Report 23; 5.10.2009) before the beginning of the 
study.
Tissue microarray and 
immunohistochemical staining
Representative multiple areas of the primary tu-
mours were selected by two pathologists (G.S. and 
R.B.) for TMA construction. Tissue cores were cho-
sen at the border of the primary tumour. Tissue cyl-
inders of 1.0 mm in diameter were taken from the 
selected regions of the donor’s paraffin block and 
were placed into a recipient paraffin block using 
a tissue-arrayer (Galileo TMA CK3500; Integrated 
Systems Engineering, Milano, Italy), as previously 
described.28 Multiple cores were taken for cases as 
representative of heterogeneous histological areas. 
Neuroendocrine differentiation (NED) was evalu-
ated using NSE, ChrA, Syp as neuroendocrine 
markers. 
Immunostainings for Ki67 (clone MIB-1; 
DakoDenmark A/S, Glostrup, Denmark), 1:200 dilu-
tion; NSE (clone E27; NeoMarker; ThermoScientific, 
Waltham, MA, USA) 1:2500; ChrA (clone LK2H10; 
NeoMarker; ThermoScientific, Waltham, MA, 
USA), 1:500; Syp (clone SY 38; Thermo-Fisher; 
ThermoScientific, Waltham, MA, USA) 1:75 were 
performed in a Lab Vision Autostainer 480S 
(Thermo Scientific, Waltham, MA, USA) with the 
UltraVision LP Large Volume Detection System 
HRP Polymer (Lab Vision Corporation, Thermo 
Scientific) according to manufacturer’s recom-
mended protocol. For evaluation of the immu-
nostaining, positively stained cells were counted 
across 3 high-power fields. Staining intensity was 
not taken into consideration. Due to technical is-
sues related to the detachment of tissue cores it 
was not possible to analyze the four biomarkers in 
all samples (Figure 1). The percentage of the posi-
tively stained cells was reported for each specimen. 
Ki67 expression was dichotomized for assessing its 
prognostic value using a cut-off of 10%.7,29
Statistical analysis
The Kaplan-Meier method was used to generate 
overall survival (OS) curves, which was defined as 
the time between the date of diagnosis and the date 
of death or the last follow-up (FU) observation. 
Patients were censored if they were still alive or 
they were lost to FU. The log-rank test was used to 
evaluate differences between groups. Association 
FIGURE 1. Determination of Ki67, NSE, CgA, SYP in primary prostate 
cancer patients. Number of concurrent biomarkers evaluated. 
The number of patients is reported above each column.
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of OS with each prognostic factor was evaluate in 
univariate and multivariate analyses by using the 
Cox proportional hazards model. All variables as-
sociated with univariate value of p ≤ 0.05 were in-
cluded in the multivariate model using a stepwise 
method. The proportional hazards assumptions 
were checked before applying the Cox regression 
model. The goodness of fit was assessed using a 
likelihood-ratio test. The discrimination ability was 
quantified by calculating the concordance index 
that ranges from 0.5 (no discrimination) to 1 (per-
fect discrimination). Possible correlations of the 
expression of Ki67 and neuroendocrine markers 
with the other prognostic variables were assessed 
by χ2 test or Wilcoxon rank sum. All statistical tests 
were performed using STATA software (StataCorp. 
2011. Stata Statistical Software: Release 12. College 
Station, TX: StataCorp LP) and p values ≤ 0.05 were 
considered as statistically significant.
Results
Neuroendocrine marker staining
NSE expression was assessable in 89 prostate can-
cer cases. Of those, 28 cases (31.5%) were com-
pletely negative, whereas 61 (68.5%) revealed a 
cytoplasmic positivity, referring to diffuse, focal 
and spotty staining (Table 1). Detachment of tissue 
cores did not allow analyzing NSE in some cases. 
ChrA was negative in 49 out of 121 cores (40.5%) 
and it was positive on the cytoplasmic level in 72 
cores (59.5%). Positive cases had weakly to highly 
diffused, or focal or spotty reactivity (Table 1). Syp 
was analyzed in 127 cases of which 44 (34.6%) were 
negative and 83 (65.4%) showed a cytoplasmic pos-
itivity, from spotty to focal to diffused (Table 1). 
Only diffused expression was considered as posi-
TABLE 1. Neuroendocrine marker staining in our cohort of 
primary prostate cancer patients
Staining
Neuroendocrine markers
NSE CgA Syp
Negative 
Diffuse 
Focal 
Spotty
28 (31.5) 
50 (56.1)
3 (3.4)
8 (9)
49 (40.5)
45 (37.2)
19 (15.7)
8 (6.6)
44 (34.6)
54 (42.5)
17 (13.4)
12 (9.5)
Total
missing
89
77
121
45
127
39
Data reported as N (%)
TABLE 2. Distribution of Ki67 positively stained cells in our cohort 
of primary prostate cancer patients
% Ki67-positive cells
Number of samples
N %
0
≤ 5
> 5 and ≤ 10
> 10 and ≤ 20
> 20 and ≤ 30
> 30
14
70
24
18
13
 7
  9.6
47.9
16.5
12.3
  8.9
  4.8
Total 146 100%
FIGURE 2. Distribution of Ki67 staining score. Positive Ki67 cells 
in TURP and prostatectomy specimens from a cohort of 166 
primary prostate cancer patients.
TABLE 3. Association between Ki67 expression and clinicopathological variables (N = 146)
Variable
Ki67 expression
≤ 10% > 10% Tot P-value
Nuclear grading
1
2
3
22
72
14
 1
23
14
23
95
28
 0.001*
Gleason Score
< 7
≥ 7
missing 1
Age at diagnosis (median, years)
     ≤ 71
     > 71
Age at diagnosis (continuous)
NSE expression
     Negative
     Positivea
missing 77
CgA expression
     Negative
     Positivea
missing 40
Syp expression
     Negative
     Positivea
missing 60
Type of intervention
     TURP
     Prostatectomy
missing 1
56
51
53
55
108
21
28
37
24
31
33
78
29
8
30
19
19
38
4
16
10
12
8
14
33
5
64
81
72
74
146
25
44
47
36
39
47
111
34
 0.001*
  0.922
  0.973
 0.073
0.217
0.326
0.081
Total 108 38 146
a Only diffuse expression was considered as positive staining; *Significant value
Radiol Oncol 2016; 50(3): 313-320.
Pascale M et al. / Prognostic markers in primary prostate cancer patients316
tive for each marker. Focal or spotty stainings were 
evaluated as negative.
No significant associations were found between 
neuroendocrine markers and clinicopathological 
variables. A slight association was revealed be-
tween NSE expression and Gleason score (p = 0.04). 
Moreover, a positive relationship was found be-
tween CgA and SYP expression (p = 0.01). The type 
of intervention was significantly associated with 
CgA (p = 0.009) and NSE (p = 0.001) expression. 
Ki67 staining
Ki67 staining analysis was measured in 146 out of 
166 prostatic cases. The median Ki67 staining score 
was 5% with an IQR of 9 whereas the mean val-
ue was 10.3% with a standard deviation of 14.2% 
(range of 0 – 90%). The percentage of the positively 
stained cells was recorded for each sample (Table 2, 
Figures 2,3). 
Ki67 was scored and stratified into two groups 
(low ≤ 10%; high > 10%) as already reported.23,24 No 
statistically significant difference was observed for 
Ki67 staining between TURP and prostatectomy 
specimens (p = 0.08). Ki67 expression was signifi-
cantly associated with Gleason score and nuclear 
grading, but not with age at diagnosis or with neu-
roendocrine markers (Table 3).
Univariate analysis
In univariate analysis, diffuse expression of NSE, 
Ki67 expression > 10%, Gleason score ≥ 7 and nu-
clear grading ≥ 2 predicted for shorter OS (Table 4).
Considering neuroendocrine markers, only 
NSE staining was significantly associated with 
OS. Patients with diffuse NSE expression had a 
reduced survival time (median OS 2 years; 95% 
CI, 2–4) compared to patients with negative ex-
pression (median OS 7; 95% CI, 5–10; p = 0.004), 
showing nearly double-fold increased risk of death 
(Table 4, Figure 4). Additionally, NED measured as 
positive at least at one of the three markers did not 
result significant.
Kaplan-Meier survival curves showed a sig-
nificant difference (p < 0.001) between low and 
high levels of Ki67 staining with median survival 
time of 6 years (95% CI, 5–9) and 2 years (95% CI, 
1–2) for patients with ≤ 10% and > 10% of positive 
cells, respectively (Figure 5A). Moreover, splitting 
group four categories according to Ki67 stain-
ing were obtained: negative, 1–10%, 11–20%, > 
20%. Negative patients showed a median overall 
survival (10 years, 95% CI: 4–9·) which was four 
years longer than in patients with Ki67 staining of 
1–10% (6 years, 95% CI: 5–8; p < 0.001) (Figure 5B). 
An improved discrimination was also reached in 
the category > 10%. Patients with Ki67 staining > 
20% were associated with a 2.5-fold increased risk 
of death, compared with patients showing Ki67 
expression of 10–20% (the overall 2-year survival 
TABLE 4. Univariate analysis of prognostic factors in patients 
with primary prostate cancer based on Cox proportional 
hazards regression model
Variable
UNIVARIATE
HR (95% CI) P-value
Nuclear grading
   2 vs 1
   3 vs 1         
1.45 (0.90-2.34)
3.49 (1.94-6.27)
   0.125
< 0.001*
Gleason score
   ≥ 7 vs < 7 2.97 (2.07-4.26) < 0.001*
Ki67 expression
   > 10% vs  ≤ 10%
Age at diagnosis
(continuous)
2.75 (1.85-4.09)
1.04 (1.02-1.07)
< 0.001*
< 0.001*
NSE expression
   Positivea vs negative
CgA expression
   Positivea vs negative
Syp expression
   Positivea vs negative
Type of intervention
   Prostatectomy vs TURP
1.99 (1.19-3.34)
0.96 (0.62-1.47)
1.18 (0.77-1.81)
0.45 (0.30-0.67)
 0.009*
0.840
0.447
< 0.001*
CI = confidence interval; HR = hazard ratio 
a Only diffuse expression was considered as positive staining; *Significant 
value
TABLE 5. Multivariate analysis of prognostic factors in patients 
with primary prostate cancer based on Cox proportional 
hazards regression model stratified by type of intervention (N 
= 144)
Variable
MULTIVARIATE
Adjusted
HR (95%CI)
Adjusted
P-value
Nuclear grading
   2 vs 1
   3 vs 1         
1.27 (0.75-2.13)
1.93 (1.01-3.68)
     0.373
     0.045*
Gleason score
   ≥ 7 vs < 7 2.41 (1.56-3.74) < 0.001*
Ki67 expression
   > 10% vs  ≤ 10%
Age at diagnosis
(continuous)
2.14 (1.41-3.25)
1.04 (1.02-1.07)
  < 0.001*
   0.001*
CI = confidence interval; HR = hazard ratio; *Significant value
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rate of 50%–95% CI: 25–70 vs 20%, 95% CI: 6–39, p 
< 0.001). These data further support the potential 
role of Ki67 immunostaining in selecting patients 
according to proliferation rate, and thus to tumor 
aggressiveness. However, we decided to assess 
the prognostic value of Ki67 for overall survival 
of prostate cancer patients by using the previous 
binary variable because of harmonization with al-
ready published studies.7,29
Age at diagnosis and type of intervention sig-
nificantly impacted on OS (p < 0.001). Thus, consid-
ering the relationship existing with other variables, 
they were included in multivariate analysis to take 
into account their possible confounding effect. 
Multivariate analysis
Multivariate analysis was done by stratifying ac-
cording to type of intervention, because of no pro-
portional risks between TURP and prostatectomy 
groups (Test of proportional-hazards assumption, 
c2 = 8.86, df = 1, p = 0.003). Ki67 expression, but not 
NSE, resulted as an independent prognostic factor 
for OS. In the final multivariable model the risk of 
death was higher for older patients (p = 0.001) with 
a nuclear grading of 3 (p = 0.04), a Gleason score ≥ 
7 (p < 0.001) and Ki67 expression > 10% (p < 0.001) 
(Table 5). Unfortunately, our dataset did not in-
clude information on PSA before surgical interven-
tion for all patients, because they were diagnosed 
many years ago before the routinely application of 
PSA screening.
Comparison of the multivariate model incorpo-
rating Ki67 expression with a base model includ-
ing conventional variables only (nuclear grading, 
Gleason score, age at diagnosis stratified by type 
of intervention) showed an improved fit which 
suggested an enhanced prognostic ability over 
the models containing clinicopathological vari-
ables only (χ2 = 11.33, df = 1, p = 0.0006). These data 
indicated that in a multivariate analysis Ki67 is a 
relevant and independent prognostic factor for OS 
of primary prostate cancer patients undergoing 
TURP or radical prostatectomy. The concordance 
index (0.72) revealed a good accuracy of the model 
in predicting OS.
Discussion
This study shows that Ki67 expression, but not 
NED, is an independent prognostic factor for OS in 
primary prostate cancer patients who underwent 
TURP or prostatectomy. 
FIGURE 3. Representative immunohistochemical staining for Ki67. (A) prostate 
adenocarcinoma with Ki67 > 10% 20 x and 40 x (B) magnification; (C) prostate 
adenocarcinoma with Ki67 ≤ 10% 20 x and 40 x (D) magnification; (E) prostate 
adenocarcinoma negative for Ki67 20 x and 40 x (F) magnification.
FIGURE 4. Survival curves by NSE staining in patients with primary prostate cancer. 
p-value from log-rank test is reported. Numbers of at risk (still alive) patients are 
indicated below the x-axis.
A B
C D
E F
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Our data demonstrate that NED, as measured 
by NSE, CgA and SYP immunohistochemistry, is 
present at the time of diagnosis in a large propor-
tion of our cohort (over 50%), but without influence 
on OS. NSE staining seems to influence OS, but it 
was not confirmed as an independent prognostic 
factor in the multivariate analysis. These results are 
consistent with current published literature where 
strong evidence of NSE as potential prognostic fac-
tor is lacking (reviewed in 6,8), especially at early 
stages.30 NED in PCa increases with higher histo-
logical grades31 and disease progression, especially 
in response to androgen deprivation therapy.32-34 
It seems that androgen deprivation therapy may 
promote the transformation of prostate adeno-
carcinoma into a neuroendocrine cancer, defined 
as t-NEPC (transformed neuroendocrine prostate 
cancer), as a mechanism of resistance.35 Ki67 ex-
pression has already been proposed as a candidate 
marker for gastroenteropancreatic36 and lung neu-
roendocrine cancers.37 An increased proliferation 
using Ki67 expression has been shown in prostate 
tumors with high NED compared to tumors with 
low or without NED.4,10,11 In this study we did not 
find any association between NED and Ki67 ex-
pression, although a trend for a positive relation-
ship between NSE staining and Ki67 expression (p 
= 0.08) has been observed.
Limitations of this study are: small sample 
size, missing data for neuroendocrine IHC, sta-
tistically significant results obtained by using the 
less specific marker for NED.9 Another limitation 
is the analysis based on mixed sample population 
of prostatectomy and TURP which was partially 
solved using a stratified Cox model to investigate 
the risk difference in two groups. Of relevance, our 
cohort represents a long-term time series which al-
lows investigating OS in cancers with a long life 
expectancy.
The prognostic significance of concurrent pres-
ence of NED features in prostate adenocarcinoma is 
currently very controversial.6 Although NED may 
have an adverse effect on prognosis of newly diag-
nosed prostate cancer, other mechanisms probably 
influence the prognosis by favoring the selection of 
the neuroendocrine pattern transformation under 
a specific stimulus, such as the pressure by andro-
gen deprivation therapy.38 The mechanisms that 
are currently involved are not known.
Interestingly, we found that cell proliferation 
measured by Ki67 staining scored as a dichoto-
mous variable with a 10% cut-off is an independent 
prognostic factor for OS in our cohort. Comparing 
prognostic models with and without Ki67 demon-
strated that Ki67 expression could yield additional 
prognostic information to that provided by conven-
tional clinicopathological parameters improving 
prognosis of prostate cancer patients. Furthermore, 
our data show that Ki67 expression correlates with 
Gleason score and nuclear grading, highlighting 
its association with prostate cancer aggressiveness, 
in agreement with others.4,23,25,39,40 Several studies 
have shown that Ki67 is useful to predict prostate 
cancer prognosis either on TURP19,23 or needle biop-
sy21,23,25,40 specimens. Furthermore, it has been pro-
posed as a candidate prognostic marker both for 
overall and specific survival endpoints17-22 as well 
as disease progression.4,17,18,20,22-27 Its prognostic rel-
FIGURE 5. Survival curves by Ki67 expression in patients with primary prostate cancer. 
(A) Ki67 staining dichotomized in ≤ 10% and > 10%; (B) Ki67 staining divided into 
negative, 1–10%, 11%–20%, > 20%. p-value from log-rank test is reported. Numbers of 
at risk (still alive) patients are indicated below the x-axis.
A
B
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evance does not seem to be influenced by therapy, 
as it has been reported to predict prognosis in pa-
tients treated by prostatectomy, alone4,24,25,27 or with 
adjuvant therapy26, or radiotherapy, alone17,22,23 or 
with androgen deprivation therapy17,18,20,22, or con-
servatively managed.19,21
Consistent with our results, Ki67 emerges as a 
powerful marker of biological aggressiveness that 
could provide supplemental prognostic informa-
tion, concerning the cellular proliferation rate, in 
addition to that provided by currently used mark-
ers, which are related to tumor pattern and exten-
sion only. Therefore, Ki67 may improve prediction 
of prostate cancer outcome based on standard clin-
ical parameters, and may help stratify and select 
patients for more aggressive treatments. The utility 
of Ki67 was also demonstrated in selecting candi-
dates with clinically insignificant cancer suitable 
for active surveillance among patients with PSA < 
4 ng/ml at diagnosis.40 The validity of Ki67 expres-
sion as an indicator of prognosis for prostate can-
cer patients in different treatment cohorts, includ-
ing both radical4,17,18,20,22-27 and conservative thera-
pies19,21, and in many investigative materials, such 
as biopsy21,23,25,40, TURP19,23 or prostatectomy4,24-27 
specimens, further supports its implementation in 
clinical practice, as recently sustained also in a me-
ta-analysis.41 However, larger prospective studies 
are needed to validate its use in routine pathology.
Despite unresolved issues on cut-offs, we sug-
gest the analysis of Ki67 in routine diagnostic prac-
tice as an additional factor for improving progno-
sis and management of prostate cancer patients.
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